ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

R-Pharm and UCB side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

R-PharmUCB
studies on the registry78581
open to participants now624
phase 3 studies under way620
reach primary completion within a year114
programswith a study of their own in two years716

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseR-PharmUCB
Phase 1

R-Pharm: 2 of its 7 programs at phase 1

  1. ocrelizumabphase 1
  2. Panitumumabphase 1
29%

UCB: 8 of its 16 programs at phase 1

  1. cizutamigphase 1
  2. Bimekizumab regimen 3 scphase 1
  3. Cizutamig will be dosed according to the protocol.phase 1
  4. CND261phase 1
  5. CND319phase 1

and 3 more — sign in to see them all

50%
Phase 2

R-Pharm: 1 of its 7 programs at phase 2

  1. RS-113phase 2
14%

UCB: 3 of its 16 programs at phase 2

  1. galvokimigphase 2
  2. glovadalenphase 2
  3. donzakimigphase 2
19%
Phase 3

R-Pharm: 4 of its 7 programs at phase 3

  1. goflikiceptphase 3
  2. olokizumabphase 3
  3. RPH-051phase 3
  4. Cetuximabphase 3
57%

UCB: 4 of its 16 programs at phase 3

  1. bimekizumabphase 3
  2. zilucoplanphase 3
  3. dapirolizumab pegolphase 3
  4. Fenfluraminephase 3
25%
Approved, new studies00%

UCB: 1 of its 16 programs at approved, new studies

  1. rozanolixizumabapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
R-Pharm1 readouts · 1 phase 3·····

R-Pharm, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. olokizumabphase 3 · Apr 9 · NCT06440746
······
UCB6 readouts · 2 phase 3·

UCB, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. UCB5285phase 1 · Dec 13 · NCT07286682
  2. bimekizumabphase 3 · Dec 21 · NCT06921850
··

UCB, Mar ’27: 1 program whose next study reaches primary completion

  1. zilucoplanphase 3 · Mar 23 · NCT06961747
·

UCB, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. rozanolixizumabapproved, new study · May 6 · NCT05063162
  2. galvokimigphase 2 · May 17 · NCT07277660

UCB, Jun ’27: 1 program whose next study reaches primary completion

  1. CND261phase 1 · Jun 1 · NCT07052032
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

R-Pharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

UCB

New programs 1

  • UCB0159phase 1 · first study · Sep 24 · Psoriasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionR-PharmUCB
Arthritis, Rheumatoidboth · compare here

R-Pharm in Arthritis, Rheumatoid: 2 programs

  1. olokizumabphase 3
  2. ocrelizumabphase 1

Their studies: R-Pharm’s studies of Arthritis, Rheumatoid in search

UCB in Arthritis, Rheumatoid: 1 program

  1. CND261phase 1

Their studies: UCB’s studies of Arthritis, Rheumatoid in search

COVID-19both · compare here

R-Pharm in COVID-19: 1 program

  1. olokizumabphase 3

Their studies: R-Pharm’s studies of COVID-19 in search

UCB in COVID-19: 1 program

  1. zilucoplanphase 3

Their studies: UCB’s studies of COVID-19 in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: R-Pharm 4 of 7 · UCB 7 of 16 programs (11 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.